Travere Therapeutics, Inc. (NASDAQ:TVTX) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Travere Therapeutics, Inc. (NASDAQ:TVTXGet Free Report) have earned an average recommendation of “Moderate Buy” from the thirteen brokerages that are covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $24.00.

Several research analysts have recently issued reports on TVTX shares. Guggenheim raised their price objective on Travere Therapeutics from $23.00 to $41.00 and gave the stock a “buy” rating in a research note on Wednesday, October 9th. Bank of America raised their price target on shares of Travere Therapeutics from $18.00 to $20.00 and gave the stock a “buy” rating in a research report on Wednesday, October 9th. Scotiabank upped their price objective on shares of Travere Therapeutics from $23.00 to $27.00 and gave the company a “sector outperform” rating in a report on Friday, November 1st. Cantor Fitzgerald initiated coverage on shares of Travere Therapeutics in a report on Friday, January 10th. They set an “overweight” rating for the company. Finally, Wells Fargo & Company upgraded shares of Travere Therapeutics from an “equal weight” rating to an “overweight” rating and boosted their target price for the company from $9.00 to $27.00 in a research report on Monday, October 21st.

Check Out Our Latest Analysis on Travere Therapeutics

Insider Buying and Selling at Travere Therapeutics

In other Travere Therapeutics news, CAO Sandra Calvin sold 15,000 shares of Travere Therapeutics stock in a transaction on Thursday, December 26th. The shares were sold at an average price of $17.22, for a total transaction of $258,300.00. Following the sale, the chief accounting officer now owns 54,927 shares of the company’s stock, valued at $945,842.94. The trade was a 21.45 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Peter Heerma sold 1,584 shares of the company’s stock in a transaction on Wednesday, January 22nd. The stock was sold at an average price of $18.94, for a total transaction of $30,000.96. Following the sale, the insider now directly owns 106,374 shares of the company’s stock, valued at $2,014,723.56. The trade was a 1.47 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 62,143 shares of company stock valued at $1,167,512. Company insiders own 3.75% of the company’s stock.

Hedge Funds Weigh In On Travere Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of TVTX. R Squared Ltd acquired a new position in shares of Travere Therapeutics during the 4th quarter worth approximately $53,000. CWM LLC boosted its stake in Travere Therapeutics by 158.5% during the third quarter. CWM LLC now owns 4,999 shares of the company’s stock worth $70,000 after buying an additional 3,065 shares during the last quarter. Quarry LP purchased a new stake in Travere Therapeutics in the 3rd quarter valued at $105,000. Forefront Analytics LLC grew its holdings in Travere Therapeutics by 10.2% in the 2nd quarter. Forefront Analytics LLC now owns 13,317 shares of the company’s stock valued at $109,000 after buying an additional 1,237 shares in the last quarter. Finally, Sei Investments Co. acquired a new stake in shares of Travere Therapeutics in the 2nd quarter worth $117,000.

Travere Therapeutics Stock Up 4.7 %

NASDAQ:TVTX opened at $21.07 on Friday. The company has a current ratio of 1.71, a quick ratio of 1.68 and a debt-to-equity ratio of 24.96. Travere Therapeutics has a twelve month low of $5.12 and a twelve month high of $21.56. The company has a market cap of $1.64 billion, a PE ratio of -4.63 and a beta of 0.70. The company’s 50 day moving average is $18.46 and its two-hundred day moving average is $15.10.

Travere Therapeutics (NASDAQ:TVTXGet Free Report) last announced its quarterly earnings data on Thursday, October 31st. The company reported ($0.70) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.71) by $0.01. Travere Therapeutics had a negative net margin of 172.75% and a negative return on equity of 537.74%. The firm had revenue of $62.90 million for the quarter, compared to analyst estimates of $60.87 million. During the same period in the previous year, the company earned ($1.17) earnings per share. The business’s quarterly revenue was up 69.6% compared to the same quarter last year. Analysts anticipate that Travere Therapeutics will post -3.92 EPS for the current year.

Travere Therapeutics Company Profile

(Get Free Report

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.

Further Reading

Analyst Recommendations for Travere Therapeutics (NASDAQ:TVTX)

Receive News & Ratings for Travere Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Travere Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.